Duquesne Family Office

← Back to your selection

All recorded activity

Rounds participated in: 4
Confirmed lead rounds: —
New companies: 4
Funding in participating rounds: $542M

By stage

Series C+3

Series B1

By primary sector

Biotech4

By country

United States4

Rounds

4 in all activity

Aug 10

Epicrispr Biotechnologies

Develops programmable epigenetic medicines to treat genetic diseases like FSHD

$90MSeries C

Role not disclosed

Jul 31

Ratio Therapeutics

Developing best-in-class radiopharmaceuticals for cancer treatment

$70MSeries C

Role not disclosed

Jun 10

SonoThera

Develops ultrasound-mediated nonviral genetic medicines

$125MSeries B

Role not disclosed

Jan 28

Cellares

Develops automated cell therapy manufacturing platforms

$257MSeries D

Role not disclosed

← Back to your selection

All recorded activity

Rounds participated in: 4
Confirmed lead rounds: —
New companies: 4
Funding in participating rounds: $542M

By stage

Series C+3

Series B1

By primary sector

Biotech4

By country

United States4

Rounds

4 in all activity

Aug 10

Epicrispr Biotechnologies

Develops programmable epigenetic medicines to treat genetic diseases like FSHD

$90MSeries C

Role not disclosed

Jul 31

Ratio Therapeutics

Developing best-in-class radiopharmaceuticals for cancer treatment

$70MSeries C

Role not disclosed

Jun 10

SonoThera

Develops ultrasound-mediated nonviral genetic medicines

$125MSeries B

Role not disclosed

Jan 28

Cellares

Develops automated cell therapy manufacturing platforms

$257MSeries D

Role not disclosed